Advanced in Bronchitis

Dr. Rajat Walia

Pulmonary Medicine | Intensive Care Medicine
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Bronchitis
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajat Walia is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Phoenix, Arizona. Dr. Walia is rated as an Advanced provider by MediFind in the treatment of Bronchitis. His top areas of expertise are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Lung Transplant, and Tissue Biopsy. Dr. Walia is currently accepting new patients.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 1 clinical trial in the study of Bronchitis.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in AZ
Hospital Affiliations
Banner Desert Medical Center
St. Joseph's Hospital And Medical Center
Chandler Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

SJHMC PHYSICIAN SERVICES
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Biological, Other
Study Drug: Prolastin C
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Pulmonary Fibrosis Foundation Patient Registry
Pulmonary Fibrosis Foundation Patient Registry
Enrollment Status: Completed
Publish Date: July 07, 2023
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

84 Total Publications

Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials.
Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials.
Journal: Transplantation
Published: October 01, 2025
Similar Doctors
Distinguished in Bronchitis
Dr. Thomas J. Slobig
Pulmonary Medicine
Distinguished in Bronchitis
Dr. Thomas J. Slobig
Pulmonary Medicine
3303 E Baseline Rd, #208, 
Gilbert, AZ 
 (19.7 miles away)
480-962-1650
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Slobig is a Pulmonary Medicine provider in Gilbert, Arizona. Dr. Slobig is rated as a Distinguished provider by MediFind in the treatment of Bronchitis. His top areas of expertise are Bronchiolitis Obliterans, Industrial Bronchitis, Bronchitis, and Tracheitis. Dr. Slobig is currently accepting new patients.

Advanced in Bronchitis
Dr. Craig M. Rundbaken
Pulmonary Medicine
Advanced in Bronchitis
Dr. Craig M. Rundbaken
Pulmonary Medicine

Craig M Rundbaken Do PLLC

14300 W Granite Valley Dr, Suite E23, 
Sun City West, AZ 
 (20.9 miles away)
623-975-0500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Rundbaken is a Pulmonary Medicine provider in Sun City West, Arizona. Dr. Rundbaken is rated as a Distinguished provider by MediFind in the treatment of Bronchitis. His top areas of expertise are Coccidioidomycosis, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, and Advanced Bronchoscopy. Dr. Rundbaken is currently accepting new patients.

Advanced in Bronchitis
Dr. Stephen N. Finberg
Pulmonary Medicine | Allergy and Immunology
Advanced in Bronchitis
Dr. Stephen N. Finberg
Pulmonary Medicine | Allergy and Immunology

Desert Center For Allergy And Chest Diseases

6970 E Chauncey Ln, Suite 100, 
Phoenix, AZ 
 (14.7 miles away)
602-788-7211
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Finberg is a Pulmonary Medicine specialist and an Allergy and Immunologist in Phoenix, Arizona. Dr. Finberg is rated as a Distinguished provider by MediFind in the treatment of Bronchitis. His top areas of expertise are Excessive Daytime Sleepiness, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Grass Allergy. Dr. Finberg is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walia's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 11 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile